Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

RAGE fusion proteins and methods of use

A technology of fusion protein and protein, which is applied in the direction of fusion polypeptide, chemical instruments and methods, and diagnosis by using light, which can solve the problem of sRAGE short half-life and achieve the effect of improving diseases

Inactive Publication Date: 2009-04-15
TRANSTECH PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when administered in vivo, sRAGE may have a half-life that may be too short to be useful for the treatment of one or more disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RAGE fusion proteins and methods of use
  • RAGE fusion proteins and methods of use
  • RAGE fusion proteins and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1A

[0262] Example 1A: Production of RAGE fusion proteins

[0263] Two plasmids were constructed for expressing RAGE-IgG fusion protein. Both plasmids were constructed by ligating different lengths of 5' cDNA sequences from human RAGE with the same 3' cDNA sequences from human IgG (γ1). These expression sequences (ie ligation products) were then inserted into the pcDNA3.1 expression vector (Invitrogen, CA). figure 2 and 3 The nucleic acid sequence encoding the RAGE fusion protein coding region is shown in . For the TTP-4000RAGE fusion protein, nucleotide sequences 1-753 (highlighted in bold) encode the RAGE N-terminal protein sequence, while nucleotide sequences 754-1386 encode the IgG protein sequence ( figure 2 ). For TTP-3000, nucleotide sequences 1-408 (highlighted in bold) encode the RAGE N-terminal protein sequence, while nucleotide sequences 409-1041 encode the IgG protein sequence ( image 3 ).

[0264] To produce the RAGE fusion protein, an expression vector com...

Embodiment 1B

[0265] Example 1B: Production of RAGE fusion proteins

[0266] A plasmid was constructed for expressing RAGE-IgG fusion protein. This plasmid was constructed by ligating the 5' cDNA sequence from human RAGE with the 3' cDNA sequence from human IgG (γ1). PCR was used to amplify cDNA. In addition, on the 5' end, the PCR primers added an Eco RI restriction enzyme site and a Kozak consensus translation initiation sequence from the cloning process. On the 3' end, the PCR primers added an Xho I restriction site immediately after the end codon. On the 3' end, the PCR primers also included 2 silent base changes that removed a cryptic RNA splice site in the immunoglobulin portion near the end codon. The codon encoding proline (based on residue 409 numbered in the protein sequence in SEQ ID NO: 32) was changed from CCG to CCC, and the codon encoding glycine (based on residue 409 in the protein sequence in SEQ ID NO: 32) Numbered residue 410) was changed from GGT to GGG. The PCR f...

Embodiment 2

[0269] Embodiment 2: the method for testing the activity of RAGE-IgG1 fusion protein

[0270] a. In vitro ligand binding:

[0271] Known RAGE ligands were coated on the surface of Maxisorb plates at a concentration of 5 μg / well. Plates were incubated overnight at 4°C. After ligand incubation, the liquid in the plate was aspirated, and a blocking buffer of 50 mM imidazole buffer (pH 7.2) containing 1% BSA was added to the plate for 1 hour at room temperature. Then aspirate the liquid in the plate and / or rinse with washing buffer (20mM imidazole, 150mM NaCl, 0.05% Tween-20, 5mM CaCl 2 and 5mM MgCl 2 , pH 7.2) for washing. A TTP-3000 (TT 3) solution with an initial concentration of 1.082 mg / mL and a TTP-4000 (TT4) solution with an initial concentration of 370 μg / mL were prepared. RAGE fusion protein was added at increasing dilutions of the starting sample. The RAGE fusion protein was allowed to incubate with the immobilized ligand for 1 hour at 37°C, after which the pla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Serial No. 60 / 771,619, filed February 9, 2006. The disclosure of US Provisional Patent Application 60 / 771,619 is hereby incorporated by reference in its entirety. field of invention [0003] The present invention relates to the regulation of the Receptor for Advanced Glycated Endproducts (RAGE). More specifically, the present invention describes fusion proteins comprising RAGE polypeptides, methods of making such fusion proteins, and the use of such proteins for the treatment of RAGE-based disorders. Background of the invention [0004] Incubation of proteins or lipids with aldose sugars results in non-enzymatic glycosylation and oxidation of amino groups on the protein to form Amadori adducts. Over time, this adduct undergoes additional rearrangements, dehydration, and cross-linking with other proteins to form complexes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/705
CPCG01N2021/638C07K2319/70A61B5/0059G01N2800/042A61B5/412G01N2800/387C07K2319/32G01J3/4412C07K14/70503G01N21/4795C07K2319/30A61B5/4088A61B5/413A61P1/04A61P13/12A61P17/06A61P19/02A61P25/00A61P25/28A61P29/00A61P31/04A61P35/00A61P37/00A61P37/06A61P9/00A61P9/10A61P3/10C07K14/705C07K14/00
Inventor A·M·M·米加里J·C·韦伯斯特R·罗恩莱因Y·E·田
Owner TRANSTECH PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com